ALIGN TECHNOLOGY, INC. Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount
ALIGN TECHNOLOGY, INC. (ALGN) reported Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount of $4.99 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-28.
Discontinued › Expense Statement › Operating Expenses
us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount · last filed 2024-02-28
- ALIGN TECHNOLOGY, INC. equity securities without readily determinable fair value, impairment loss, annual amount for the quarter ending 2021-06-30 was $0.00, a 100.00% decline year-over-year.
- ALIGN TECHNOLOGY, INC. equity securities without readily determinable fair value, impairment loss, annual amount for the quarter ending 2021-03-31 was $0.00, a 100.00% decline year-over-year.
- ALIGN TECHNOLOGY, INC. equity securities without readily determinable fair value, impairment loss, annual amount for the quarter ending 2020-12-31 was $2.10M.
- ALIGN TECHNOLOGY, INC. equity securities without readily determinable fair value, impairment loss, annual amount for the quarter ending 2020-09-30 was $0.00.
- ALIGN TECHNOLOGY, INC. equity securities without readily determinable fair value, impairment loss, annual amount for fiscal 2023 was $4.99M.
- ALIGN TECHNOLOGY, INC. equity securities without readily determinable fair value, impairment loss, annual amount for fiscal 2022 was $0.00.
- ALIGN TECHNOLOGY, INC. equity securities without readily determinable fair value, impairment loss, annual amount for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- ALIGN TECHNOLOGY, INC. equity securities without readily determinable fair value, impairment loss, annual amount for fiscal 2020 was $5.89M, a 48.10% increase from fiscal 2019.
| Period end | Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 3 month | Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 6 month | Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 9 month | Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 12 month |
|---|---|---|---|---|
| 2023-12-31 | $4.99M 10-K · filed 2024-02-28 | |||
| 2022-12-31 | $0.00 10-K · filed 2024-02-28 | |||
| 2021-12-31 | $0.00 10-K · filed 2024-02-28 | |||
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $0.00 10-Q · filed 2021-08-04 | $2.10M derived: sum of 3 quarters · filed 2021-08-04 | $2.10M derived: sum of 4 quarters · filed 2021-08-04 |
| 2021-03-31 | $0.00 10-Q · filed 2021-05-05 | $2.10M derived: sum of 2 quarters · filed 2021-05-05 | $2.10M derived: sum of 3 quarters · filed 2021-05-05 | $2.99M derived: sum of 4 quarters · filed 2021-08-04 |
| 2020-12-31 | $2.10M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $2.10M derived: sum of 2 quarters · filed 2021-02-26 | $2.99M derived: sum of 3 quarters · filed 2021-08-04 | $5.89M 10-K · filed 2021-02-26 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-30 | $887.00K derived: sum of 2 quarters · filed 2021-08-04 | $3.79M 10-Q · filed 2020-10-30 | $3.79M derived: sum of 4 quarters · filed 2021-08-04 |
| 2020-06-30 | $887.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $3.79M 10-Q · filed 2021-08-04 | $3.79M derived: sum of 3 quarters · filed 2021-08-04 | $3.79M derived: sum of 4 quarters · filed 2021-08-04 |
| 2020-03-31 | $2.90M 10-Q · filed 2021-05-05 | $2.90M derived: sum of 2 quarters · filed 2021-05-05 | $2.90M derived: sum of 3 quarters · filed 2021-05-05 | |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $0.00 derived: sum of 2 quarters · filed 2021-02-26 | $3.98M 10-K · filed 2021-02-26 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-30 | $3.98M 10-Q · filed 2020-10-30 | ||
| 2019-06-30 | $3.98M 10-Q · filed 2020-07-31 | |||
| 2018-12-31 | $0.00 10-K · filed 2021-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MSA Safety Inc (MSA) | United States | $7.023B | 21.47 |
| ZIMMER BIOMET HOLDINGS, INC. (ZBH) | United States | $17.103B | 20.66 |
| ESTABLISHMENT LABS HOLDINGS INC. (ESTA) | $1.954B | -65.76 | |
| Cadre Holdings, Inc. (CDRE) | United States | $1.123B | 33.88 |
| Enovis CORP (ENOV) | United States | $1.053B | -1.18 |
| Anteris Technologies Global Corp. (AVR) | United States | $0.746B | |
| STERIS plc (STE) | Ireland | $20.343B | 25.49 |
| Sanara MedTech Inc. (SMTI) | United States | $0.323B | -6.81 |
| Inogen Inc (INGN) | United States | $0.139B | -7.00 |
| Conexeu Sciences Inc. (CNXU) | United States | $0.111B |